ClosedNo longer accepting applications
Medication-Assisted Treatment - Prescription Drug and Opioid Addiction
Substance Abuse and Mental Health Services Adminis
This opportunity closed July 27, 2026. 3 similar opportunities are open right now.
Similar opportunities open now
- FY 2026 DRUG COURT TRAINING AND TECHNICAL ASSISTANCE COMPETITIVE COOPERATIVE AGREEMENT SOLICITATIONOpenOffice of National Drug Control PolicyCloses in 12 daysUp to $6M
- Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed)OpenNational Institutes of HealthCloses in 46 days
- HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)OpenNational Institutes of HealthCloses Feb 2029
About this archived opportunity
The purpose of this program is to expand and enhance access to Medications for Opioid Use Disorder (MOUD), increasing access to treatment and recovery for individuals with Opioid Use Disorder (OUD) and decreasing illicit opioid use, prescription opioid misuse and overdose.
Historical details
- Status
- Closed
- Deadline
- July 27, 2026
- First captured
- March 20, 2026
- Award
- $750,000
- Publisher reference
- 361578
Eligibility: Domestic public and private nonprofit entities, including faith-based organizations.
Free. One email, sent if this program reopens or a close match to it opens. We watch for 12 months, then stop. No list.
Related opportunities
- FY 2026 DRUG COURT TRAINING AND TECHNICAL ASSISTANCE COMPETITIVE COOPERATIVE AGREEMENT SOLICITATIONOffice of National Drug Control PolicyCloses in 12 daysUp to $6M
- Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed)National Institutes of HealthCloses in 46 days
- HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)National Institutes of HealthCloses Feb 2029